Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Schlenk · SciRah

Researcher profile · Semantic Scholar

R. Schlenk

Share profile

R. Schlenk — researcher profile on SciRah

h-index: 85
Works: 568
Citations: 37K

Most-cited papers

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
H. Erba, P. Montesinos, Hee-Je Kim, E. Patkowska +18 more
2023The Lancet329 citations
Semantic Scholar
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
D. Tamborero, R. Dienstmann, M. Rachid, J. Boekel +28 more
2022Nature Cancer117 citations Open access
Semantic Scholar
Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
A. Waclawiczek, Aino-Maija Leppä, S. Renders, Karolin Stumpf +20 more
2023Cancer Discovery95 citations Open access
Semantic Scholar
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
C. Denkinger, M. Janssen, U. Schäkel, Julia Gall +50 more
2022Nature Cancer69 citations Open access
Semantic Scholar
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.
A. Jahn, A. Rump, T. Widmann, C. Heining +73 more
2022Annals of Oncology64 citations Open access
Semantic Scholar
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
H. Döhner, D. Weber, J. Krzykalla, W. Fiedler +33 more
2023The Lancet Haematology55 citations
Semantic Scholar
Overlapping features of therapy-related and de novoNPM1-mutated AML.
J. Othman, M. Meggendorfer, E. Tiacci, C. Thiede +27 more
2022Blood41 citations Open access
Semantic Scholar
Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question
S. Jaramillo, R. Schlenk
2023Haematologica37 citations Open access
Semantic Scholar
Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
M. Rohnert, M. Kramer, Jonas Schadt, P. Ensel +12 more
2022Leukemia30 citations Open access
Semantic Scholar
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin
S. Kayser, C. Sartor, Marlise R. Luskin, Jonathan A. Webster +10 more
2022Haematologica27 citations Open access
Semantic Scholar
S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML
H. Erba, P. Montesinos, R. Vrhovac, E. Patkowska +16 more
2022HemaSphere27 citations Open access
Semantic Scholar
Acute myeloid leukemia: introduction to a series highlighting progress and ongoing challenges
R. Schlenk
2023Haematologica25 citations Open access
Semantic Scholar
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
Frank G. Rücker, Lars Bullinger, S. Cocciardi, Sabrina Skambraks +27 more
2024Blood Advances23 citations Open access
Semantic Scholar
Predicting Successful Hematopoietic Stem Cell Collection in Healthy Allogeneic Donors
S. Kayser, R. Schlenk, M. Steiner, H. Klüter +1 more
2023Transfusion Medicine and Hemotherapy23 citations Open access
Semantic Scholar
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease
S. Kayser, C. Sartor, F. Giglio, A. Bruno +15 more
2023Haematologica21 citations Open access
Semantic Scholar
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial
R. Schlenk, P. Montesinos, Hee-je Kim, Antonio Romero-Aguilar +17 more
2025Haematologica19 citations Open access
Semantic Scholar
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML
J. Unglaub, R. Schlenk, J. Middeke, Stefan W. Krause +15 more
2024Blood Advances17 citations Open access
Semantic Scholar
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
J. Heitmann, R. Schlenk, D. Dörfel, S. Kayser +14 more
2023Journal of Hematology & Oncology17 citations Open access
Semantic Scholar
FLT3-ITD measurable residual disease from the QuANTUM-First trial
M. Levis, Harry P. Erba, P. Montesinos, Hee-Je Kim +17 more
2025Blood Advances15 citations Open access
Semantic Scholar
Real‐world data for precision cancer medicine—A European perspective
P. Christopoulos, R. Schlenk, Daniel Kazdal, M. Blasi +12 more
2023Genes, Chromosomes and Cancer15 citations Open access
Semantic Scholar
Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
M. Janssen, A. Leo, C. Wolf, Miriam Stenzinger +8 more
2024International Journal of Cancer12 citations Open access
Semantic Scholar
Comprehensive assessment of endothelial dysfunction before cellular therapy: EASIX, local imaging, and systemic biomarkers
Laura Simons, L. Alasfar, Muath Qadoura, Jule Buhl +12 more
2025Blood vessels, thrombosis & hemostasis11 citations
Semantic Scholar
10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
Richard M. Stone, Jun Yin, S. Mandrekar, A. Benner +27 more
2024Blood11 citations Open access
Semantic Scholar
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/ hypomethylating agents
S. Kayser, K. Sanber, G. Marconi, Agnese Mattei +17 more
2024Haematologica10 citations Open access
Semantic Scholar
Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia
R. Schlenk, D. Weber, J. Krzykalla, T. Kindler +17 more
2023Scientific Reports9 citations Open access
Semantic Scholar
Public and patient involvement: a survey on knowledge, experience and opinions among researchers within a precision oncology European project
P. Mosconi, C. Colombo, Pasquale Paletta, L. Gangeri +103 more
2023BMC Cancer9 citations Open access
Semantic Scholar
Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival
M. Levis, H. Erba, P. Montesinos, R. Vrhovac +17 more
2022Blood9 citations
Semantic Scholar
Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
Maximilian Schmutz, Manuela Zucknick, R. Schlenk, D. Mertens +7 more
2023Clinical Epigenetics8 citations Open access
Semantic Scholar
Abstract CT141: CC-1, a bispecific PSMAxCD3 antibody for treatment of prostate carcinoma: Results of the ongoing phase I dose escalation trial
J. Heitmann, J. Walz, Martin Pflügler, M. Marconato +6 more
2022Cancer Research8 citations
Semantic Scholar
CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial
M. Teleanu, C. Heilig, S. Pirmann, R. Hamacher +21 more
2025ESMO Open7 citations Open access
Semantic Scholar
Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD-Negative Acute Myeloid Leukemia
P. Montesinos, June-Won Cheong, N. Daver, Amir T. Fathi +16 more
2024Blood7 citations
Semantic Scholar
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All‐Trans Retinoic Acid or Valproic Acid to Decitabine
H. Bresser, C. Schmoor, O. Grishina, Dietmar Pfeifer +30 more
2024European Journal of Haematology7 citations Open access
Semantic Scholar
Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial
R. Schlenk, P. Montesinos, Antonio Romero-Aguilar, R. Vrhovac +17 more
2022Blood7 citations
Semantic Scholar
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO
A. Kubasch, A. Giagounidis, G. Metzgeroth, A. Jonášová +25 more
2022Leukemia7 citations Open access
Semantic Scholar
Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)
M. Levis, Harry P. Erba, P. Montesinos, Elzbieta Patkowska +12 more
2024Blood6 citations
Semantic Scholar
Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase
D. Heudobler, F. Lüke, J. Hahn, M. Grube +13 more
2023Haematologica6 citations Open access
Semantic Scholar
AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3-Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML).
H. Erba, P. Montesinos, R. Vrhovac, E. Patkowska +16 more
2022Clinical Lymphoma, Myeloma & Leukemia6 citations
Semantic Scholar
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial
L. Bunse, Katharina Lindner, A. Wick, A. Freitag +23 more
2026Nature Cancer5 citations Open access
Semantic Scholar
Quizartinib for patients with newly diagnosed FLT3-ITD–positive AML who received maintenance therapy in QuANTUM-First
M. Levis, Harry P. Erba, P. Montesinos, Elżbieta Patkowska +12 more
2026Blood Advances5 citations Open access
Semantic Scholar
Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3-ITD+ AML Patients (pts
A. Perl, H. Erba, P. Montesinos, R. Vrhovac +17 more
2023Blood5 citations
Semantic Scholar
Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
L. Ruhnke, C. Röllig, S. Herold, T. Sauer +24 more
2023Haematologica5 citations Open access
Semantic Scholar
P1024: MYLOX-1: A PHASE II STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR GB2064 (WITH FOCUS ON BONE MARROW COLLAGEN) IN PATIENTS WITH MYELOFIBROSIS
C. Harrison, J. Mascarenhas, D. Cilloni, R. Schlenk +7 more
2023HemaSphere5 citations Open access
Semantic Scholar
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
Sonia Jaramillo, L. Le Cornet, M. Kratzmann, Johannes Krisam +22 more
2023Trials5 citations Open access
Semantic Scholar
Gene expression-based prediction of pazopanib efficacy in sarcoma.
C. Heilig, A. Lassmann, S. Mughal, A. Mock +43 more
2022European Journal of Cancer5 citations
Semantic Scholar
Differential Immunoexpression of Inhibitory Immune Checkpoint Molecules and Clinicopathological Correlates in Keratoacanthoma, Primary Cutaneous Squamous Cell Carcinoma and Metastases
A. Lonsdorf, D. Edelmann, T. Albrecht, A. Brobeil +6 more
2024Acta Dermato-Venereologica4 citations Open access
Semantic Scholar
P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL
M. Levis, H. Erba, P. Montesinos, R. Vrhovac +17 more
2023HemaSphere4 citations Open access
Semantic Scholar
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia
S. Kayser, D. Martínez-Cuadrón, R. Rodríguez-Veiga, M. Hänel +28 more
2023Haematologica4 citations Open access
Semantic Scholar
Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
V. Gaidzik, P. Paschka, R. Schlenk, D. Weber +13 more
2023HemaSphere4 citations Open access
Semantic Scholar
Atypical presentation of patients with chronic myeloid leukemia in chronic phase—Case report
Florian Ramdohr, A. Fabarius, B. Maier, Daniela Bretschneider +6 more
2022Frontiers in Oncology4 citations Open access
Semantic Scholar
Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
Sonia Jaramillo Segura, M. Wass, J. Schaffrath, K. Rieger +49 more
2022Blood4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Levis×15
Invite
M. Levis — researcher profile on SciRah
Li Liu×11
Invite
Li Liu — researcher profile on SciRah
C. Müller-Tidow×11
Invite
C. Müller-Tidow — researcher profile on SciRah
A. Lesegretain×9
Invite
A. Lesegretain — researcher profile on SciRah

×9

Invite

M. Sekeres — researcher profile on SciRah

P. Montesinos×8

Invite

P. Montesinos — researcher profile on SciRah

Invite

R. Vrhovac — researcher profile on SciRah

Invite

C. Röllig — researcher profile on SciRah

Invite

K. Döhner — researcher profile on SciRah

Invite

H. Erba — researcher profile on SciRah

Invite

Po-Nan Wang — researcher profile on SciRah

Invite

J. Hanyok — researcher profile on SciRah